Parker Waichman LLP

More Vytorin Questions from Congress

A Vytorin probe in Congress is expanding in scope.  The House Energy and Commerce Committee has been investigating the safety and effectiveness of the controversial cholesterol drug for months, and now it wants to hear from the statistician who analyzed data on cancer cases and deaths in the SEAS study and two other ongoing Vytorin studies. […]

A <"https://www.yourlawyer.com/topics/overview/vytorin">Vytorin probe in Congress is expanding in scope.  The House Energy and Commerce Committee has been investigating the safety and effectiveness of the controversial cholesterol drug for months, and now it wants to hear from the statistician who analyzed data on cancer cases and deaths in the SEAS study and two other ongoing Vytorin studies.

The latest Vytorin controversy followed the release of the SEAS study, which was designed to see if the drug prevented heart attacks in people with aortic stenosis.  Not only did SEAS show that Vytorin offered no additional heart attack prevention, but Vytorin patients enrolled in the study had higher rates of cancer than those taking a placebo. In the trial 102 patients taking Vytorin developed cancer, compared with 67 taking the placebo. Of those, 39 people taking Vytorin died from their cancer, compared with 23 taking placebo.

Researchers conducting the study said that while those numbers don’t prove a definitive cancer link, they were “statistically significant, meaning the odds were less than 5 percent that they were the result of chance.

Merck and Schering-Plough, the makers of Vytorin, have called the cancer findings an anomaly.  The companies base that claim on an analysis of the SEAS cancer findings that was conducted by Richard Peto, an Oxford University statistician.  Peto pooled data from two much larger ongoing studies of Vytorin and said they showed that the cancer risk was a statistical fluke. He called the contention that Vytorin could cause cancer “bizarre”.

But Peto’s conclusions have come under fire.  This week, when SEAS was published in the New England Journal of Medicine, the editors of the journal also published a strongly worded editorial criticizing Peto’s findings.  The authors of the editorial wrote that a link to cancer deaths “should not be assumed to be a chance finding until further data are in,”, adding that doctors and patients “are unfortunately left for now with uncertainty about the safety and efficacy of the drug.”

In a letter sent to Merck CEO Richard T. Clark and Schering-Plough CEO Fred Hassan this week, the  House committee directs the companies to answer questions about the SEAS cancer findings, and Peto’s report. The letter states that the committee had expected “a complete assessment of Vytorin’s association with cancer in the SEAS study,” but only got a five-page report, relayed by the Food and Drug Administration on Aug. 21, that contained little more information than what Peto already had released publicly.”

According to a report in the Associated Press, a spokesperson for Schering-Plough indicated that while the company has not responded to the Committees Aug. 21 request for more information, it plans to do so, and is preparing a response.  As far as Peto appearing to answer the committee’s questions, the spokesperson said that he does not work for Schering-Plough, and the company does not control his activities.

The House Energy and Finance Committee has been investing Vytorin since late last year, when questions were raised about Merck and Schering-Ploughs handling of another key Vytorin study.  That study, ENHANCE, which was finally released in January, showed Vytorin was ineffective in preventing clogged arteries, and might actually increase plaque in some users.  Some  Vytorin critics have compared the companies’ decision to delay the release of ENANCE for over a year to fraud.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
I thank parker and waichman team for work so hard on my case Joonho hong, Josephine Burgess,Juila,joanne Stevens THANK YOU FOR A GREAT JOB IF I NEED ANOTHER TEAM IT WILL BE PARKER WAICHMAN HAPPY SUMMER
BRYANT LEE
5 years ago
5 Star Reviews 150
PW WAS FANTASTIC WHILE HANDLING MY WTC CASE. SHELLEY DAVIS WAS SUPERB, SHE MANAGED THE CASE WITH VERY LITTLE INPUT FROM ME. SHE CONTACTED ME WITH UPDATES AND WAS ALWAYS AVAILABLE TO ME WHENEVER I CALLED WITH A QUESTION. IF YOU HAVE A WTC CASE, JUST CALL THEM AND THEY WILL TAKE CARE OF ALL THE COMMUNICATING. IF ALL GOES WELL THEY SHOULD HAVE AN AWARD FOR YOU WITHIN 18 MONTHS. I AM VERY HAPPY THAT I CHOSE PW.
RAUL MORALES
3 years ago
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness , Value I am Very Satisfied with my experience that I have had with the Firm.The Paralegal assigned to my case is Christina Morace, she is excellent.She was very responsive to all of my inquires and always made me feel like I was her only client. In my opinion she should be a Valued Employee at the Firm, she represents PW very well.
Frank V. DeGarcia
2 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038